ASCO 2026 | OrigAMI-4: dual EGFR/MET targeting demonstrates durable responses in pretreated HNSCC
Barbara Burtness, MD, Yale School of Medicine, New Haven, CT, comments on the OrigAMI-4 trial (NCT06385080), a multi-cohort study investigating subcutaneous amivantamab and hyaluronidase-lpuj in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Dr Burtness presents pivotal results showing a investigator-assessed objective response rate (ORR) of 42%, highlighting that co-targeting EGFR and MET appears to be of utility in head and neck cancer, with amivantamab demonstrating impressive clinical activity and a favorable safety profile. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
